Raymond James downgrades Aspreva Pharmaceuticals (ASPV) to Market Perform
ASPV Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Raymond James downgrades Aspreva Pharmaceuticals (NASDAQ: ASPV) from Outperform to Market Perform with a $26 price target.
Aspreva Pharmaceuticals is a pharmaceutical company focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications.
Aspreva Pharmaceuticals is a pharmaceutical company focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
- UBS Maintains a 'Buy' on Teva Pharma (TEVA); CEO Highlights From Conference Call
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
